US FDA asked to explain management of "disclosed conflicts" in trials
This article was originally published in Clinica
Executive Summary
US Senator Chuck Grassley (Republican – Iowa) has asked the FDA to explain how it handles reports of payments made by drug and device companies to doctors participating in clinical trials of their products to minimise potential bias.